Featured Research

from universities, journals, and other organizations

HBV Genotype B/B3 And C/C1 Are The Major Genotypes In Indonesia?

Date:
September 16, 2009
Source:
World Journal of Gastroenterology
Summary:
A research team from Indonesia identified the distribution of hepatitis B virus subgenotype and basal core promoter mutations among patients with HBV-associated liver disease in Indonesia. They found HBV genotype B/B3 and C/C1 are the major genotypes in Indonesia. Mutations in BCP, such as A1762T/G1764A and T1753V, might have an association with manifestations of liver disease.

Previous studies revealed that HBV genotypes as well as mutations in the core promoter, precore or HBx gene have been shown to have an association with the clinical outcome of liver disease, however, this is still controversial. It is likely that this depends on the HBV genotype distribution in certain region. So far, there is no such data from Indonesia, which is a big country with a big population and a relatively high HBV carrier rate.

A research article to be published on August 28, 2009 in the World Journal of Gastroenterology addresses this question. The research team led by Dr. Utama from Mochtar Riady Institute for Nanotechnology, used samples from HBV-associated liver disease patients [chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC)]collected from several centers, to study the association between HBV genotype and mutations and clinical outcome of liver disease.

The study demonstrated that only HBV genotype B and C were detected among HBV-associated liver disease patients in Indonesia, and genotype B was predominant. It was found that HBV genotype, as well as the serotype, might not be associated with an increased risk of HCC. The double mutation (A1762T/G1764A) was associated with progression of liver disease, while T1753V mutation could be used as an indicator of liver cirrhosis rather than HCC.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Utama et al. Hepatitis B virus subgenotypes and basal core promoter mutations in Indonesia. World Journal of Gastroenterology, 2009; 15 (32): 4028 DOI: 10.3748/wjg.15.4028

Cite This Page:

World Journal of Gastroenterology. "HBV Genotype B/B3 And C/C1 Are The Major Genotypes In Indonesia?." ScienceDaily. ScienceDaily, 16 September 2009. <www.sciencedaily.com/releases/2009/09/090916090904.htm>.
World Journal of Gastroenterology. (2009, September 16). HBV Genotype B/B3 And C/C1 Are The Major Genotypes In Indonesia?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/09/090916090904.htm
World Journal of Gastroenterology. "HBV Genotype B/B3 And C/C1 Are The Major Genotypes In Indonesia?." ScienceDaily. www.sciencedaily.com/releases/2009/09/090916090904.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins